- idUS
- Listar por autor
Listar por autor "Ray, Kausik K."
Mostrando ítems 1-4 de 4
-
Artículo
A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia
Brandts, Julia; Dharmayat, Kanika I.; Vallejo Vaz, Antonio Javier; Azar Sharabiani, Mansour Taghavi; Jones, Rebecca; Kastelein, John J.P.; Raal, Frederick J.; Ray, Kausik K. (Elsevier Ireland, 2021)Background and aims Several medications targeting PCSK9 reduce LDL-cholesterol (LDL-C) in heterozygous familial ...
-
Artículo
Implications of ACC/AHA Versus ESC/EAS LDL‑C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI
Vallejo Vaz, Antonio Javier; Bray, Sarah; Villa, Guillermo; Brandts, Julia; Kiru, Gaia; Murphy, Jennifer; Ray, Kausik K. (Springer, 2022)Purpose Low-density lipoprotein cholesterol (LDL-C) recommendations difer between the 2018 American College of Cardi ...
-
Artículo
Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution?
Stevens, Christophe A T; Vallejo Vaz, Antonio Javier; Chora, Joana R; Barkas, Fotis; Brandts, Julia; Mahani, Alireza; Abar, Leila; Sharabiani, Mansour T A; Ray, Kausik K. (Wiley, 2024)BACKGROUND: Familial hypercholesterolemia (FH), while highly prevalent, is a significantly underdiagnosed monogenic ...
-
Artículo
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial
Vallejo Vaz, Antonio Javier; Packard, Chris J.; Ference, Brian A.; Santos, Raúl D.; Kastelein, John J. P.; Stein, Evan A.; Ray, Kausik K. (Elsevier, 2021-03)Background and aims: Trial evidence for the benefits of cholesterol-lowering is limited for familial hypercho lesterolemia ...